Paroxysmal supraventricular tachycardia pathophysiology: Difference between revisions
Noha Elzeiny (talk | contribs) |
Noha Elzeiny (talk | contribs) |
||
| Line 38: | Line 38: | ||
===Pathogenesis=== | ===Pathogenesis=== | ||
Reentry is the most prevalent cause of PSVT. | Reentry is the most prevalent cause of PSVT. less commonly., abnormal impulse formation '''<ref name=":0">Hafeez Y, Grossman SA. Paroxysmal Supraventricular (PSVT) [Updated 2019 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <nowiki>https://www.ncbi.nlm.nih.gov/books/NBK507699</nowiki></ref>.''' | ||
Reentry circuts: | |||
Abnormal impulse formation <ref>Friedewald V.E. (2016) Supraventricular Tachycardia: (SVT/Paroxysmal Supraventicular Tachycardia/PSVT). In: Clinical Guide to Cardiovascular Disease. Springer, London</ref>.: | |||
Enhanced or ectopic pace maker | |||
Trigere activity | |||
Early after-depolarization, which is promoted by: | |||
Slow heart rate | |||
Decreased or increased outward current | |||
Delayed after-depolarization due to | |||
Intracellular Ca++ overload | |||
<br /> | <br /> | ||
==Genetics== | ==Genetics== | ||
Revision as of 23:19, 16 July 2020
|
Paroxysmal supraventricular tachycardia Microchapters |
|
Differentiating Paroxysmal supraventricular tachycardia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Paroxysmal supraventricular tachycardia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Paroxysmal supraventricular tachycardia pathophysiology |
|
FDA on Paroxysmal supraventricular tachycardia pathophysiology |
|
CDC on Paroxysmal supraventricular tachycardia pathophysiology |
|
Paroxysmal supraventricular tachycardia pathophysiology in the news |
|
Blogs on Paroxysmal supraventricular tachycardia pathophysiology |
|
Risk calculators and risk factors for Paroxysmal supraventricular tachycardia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Noha Elzeiny, M.B.B.Ch, M.Sc.[2]
Overview
The exact pathogenesis of [disease name] is not fully understood.
OR
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
OR
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
OR
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
OR
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
OR
The progression to [disease name] usually involves the [molecular pathway].
OR
The pathophysiology of [disease/malignancy] depends on the histological subtype.
Pathophysiology
Physiology
The normal physiology of PSVT can be understood as follows:
The sinoatrial (SA) node generates electrical impulses. These electrical impulses propagate through the atria. The electrical impulse travels in an ِAnterograde direction to the ventricles via the atrioventricular (AV) node. The AV node has a physiologic delay in impulse conduction, and this delay is essential for synchronized contractions between atria and ventricles [1][2] . The fact that adjacent conduction pathways have the same refractory periods, ensures normal impulse propagation at optimum speed for synchronous AV contraction. Any change in the refractory period between adjacent conduction pathways creates a reentry circuit composed of one pathway for anterograde conduction and the other pathway for retrograde conduction[3].
Pathogenesis
Reentry is the most prevalent cause of PSVT. less commonly., abnormal impulse formation [4].
Reentry circuts:
Abnormal impulse formation [5].:
Enhanced or ectopic pace maker
Trigere activity
Early after-depolarization, which is promoted by:
Slow heart rate
Decreased or increased outward current
Delayed after-depolarization due to
Intracellular Ca++ overload
Genetics
[Disease name] is transmitted in [mode of genetic transmission] pattern.
OR
Genes involved in the pathogenesis of [disease name] include:
- [Gene1]
- [Gene2]
- [Gene3]
OR
The development of [disease name] is the result of multiple genetic mutations such as:
- [Mutation 1]
- [Mutation 2]
- [Mutation 3]
Associated Conditions
Conditions associated with [disease name] include:
- [Condition 1]
- [Condition 2]
- [Condition 3]
Gross Pathology
On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Microscopic Pathology
On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
References
- ↑ Al-Zaiti, S. S., & Magdic, K. S. (2016). Paroxysmal Supraventricular Tachycardia. Critical Care Nursing Clinics of North America, 28(3), 309–316. doi:10.1016/j.cnc.2016.04.005
- ↑ Anderson, R. H., & Mori, S. (2016). Wilhelm His Junior and his bundle. Journal of Electrocardiology, 49(5), 637–643
- ↑ Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation. 2003;107(8):1096-1099. doi:10.1161/01.cir.0000059743.36226.e8
- ↑ Hafeez Y, Grossman SA. Paroxysmal Supraventricular (PSVT) [Updated 2019 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507699
- ↑ Friedewald V.E. (2016) Supraventricular Tachycardia: (SVT/Paroxysmal Supraventicular Tachycardia/PSVT). In: Clinical Guide to Cardiovascular Disease. Springer, London